The effect on clearance of levetiracetam (LEV) was estimated in women with epilepsy of childbearing potential using oral contraceptives (OCs). The estimated clearance (plasma concentration/daily dose) was 39 nmol/L/mg (range 14-88 nmol/L/mg) among women who did not use OC (n=30) and 38 nmol/L/mg (range 18-103 nmol/L/mg) among OC users (n=23) (p=0.8). In conclusion, combing LEV and OCs seems safe from a pharmacokinetic perspective.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.eplepsyres.2011.04.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cardiometabolic Index and Stress Urinary Incontinence in US Women: The Mediating Role of the Triglyceride Glucose Index.
Int Urogynecol J
January 2025
The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China.
Background: Stress urinary incontinence (SUI) is a prevalent condition among women, significantly impairing their quality of life. Emerging evidence suggests that metabolic dysfunction may play a role in the development of SUI, although the underlying mechanisms remain unclear. This study aims to examine the association between the cardiometabolic index (CMI), a novel marker of metabolic health, and the risk of SUI in women.
View Article and Find Full Text PDFEffects of 24-Hour Diet- or Exercise-Induced Energy Availability Manipulations on Substrate Utilization and Performance.
Med Sci Sports Exerc
November 2024
Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, VIC, AUSTRALIA.
Purpose: To examine sex-based differences in substrate oxidation, postprandial metabolism, and performance in response to 24-hour manipulations in energy availability (EA), induced by manipulations to energy intake (EI) or exercise energy expenditure (EEE).
Methods: In a Latin Square design, 20 endurance athletes (10 females using monophasic oral contraceptives and 10 males) undertook five trials, each comprising three consecutive days. Day one was a standardized period of high EA; EA was then manipulated on day two; post-intervention testing occurred on day three.
Selective progesterone receptor modulators for the treatment of dysmenorrhea: an update.
Expert Opin Pharmacother
January 2025
Department of Obstetrics and Gynecology, University of Florence, Careggi University Hospital, Florence, Italy.
Introduction: Dysmenorrhea is a painful symptom associated with uterine contractions and menstrual bleeding and is treated by administering analgesic drugs. Since progesterone receptors (PRs) have a major role in regulating uterine tissues (myometrium and endometrium) oral contraceptives are used off-label for treating primary or secondary dysmenorrhea. The development of selective progesterone receptor modulators (SPRMs) a class of synthetic steroids with agonistic, antagonistic, or mixed effects in targeting PRs in different tissues stimulated their possible clinical use for treating secondary dysmenorrhea related to uterine diseases (endometriosis, adenomyosis, uterine fibroids).
View Article and Find Full Text PDFThe relationship between hormonal contraceptives, level of anxiety and emotional awareness: pilot project.
Physiol Res
December 2024
Department of Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
An important part of the side effects of combined oral contraceptives (COC) usage is its psychological impact, which includes mood changes, anxiousness and depression. The psychological impacts are expected to be caused by physiological fluctuations of sex hormone levels during the menstrual cycle; this cycling is, however, suppressed in COC users. In our study, we assessed the differences in emotional awareness and anxiousness between women long term users of anti-androgenic COC (AA) and women with no COC use in their medical history (C).
View Article and Find Full Text PDFLong-acting, progestin-based contraceptives and risk of breast, gynecological, and other cancers.
J Natl Cancer Inst
January 2025
School of Public Health, University of Queensland, Brisbane, QLD 4006, Australia.
Background: Use of long-acting, reversible contraceptives has increased over the past 20 years, but an understanding of how they could influence cancer risk is limited.
Methods: We conducted a nested case-control study among a national cohort of Australian women (n = 176 601 diagnosed with cancer between 2004 and 2013; 882 999 matched control individuals) to investigate the associations between the levonorgestrel intrauterine system, etonogestrel implants, depot-medroxyprogesterone acetate and cancer risk and compared these results with the oral contraceptive pill. We used conditional logistic regression to estimate odds ratios (OR) and 95% confidence intervals (CI).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!